Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19

INTRODUCTION: COVID-19 may cause severe pneumonitis and trigger a massive inflammatory response that requires ventilatory support. The intensive care unit (ICU)-mortality has been reported to be as high as 62%. Dexamethasone is the only of all anti-inflammatory drugs that have been tested to date th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjellberg, Anders, Douglas, Johan, Pawlik, Michael T, Kraus, Michael, Oscarsson, Nicklas, Zheng, Xiaowei, Bergman, Peter, Frånberg, Oskar, Kowalski, Jan H, Nyren, Sven Paul, Silvanius, Mårten, Skold, Magnus, Catrina, Sergiu-Bogdan, Rodriguez-Wallberg, Kenny A, Lindholm, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260306/
https://www.ncbi.nlm.nih.gov/pubmed/34226219
http://dx.doi.org/10.1136/bmjopen-2020-046738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260306/
https://www.ncbi.nlm.nih.gov/pubmed/34226219
http://dx.doi.org/10.1136/bmjopen-2020-046738

Ejemplares similares